European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
Intellasia,
11-Nov-2022 Intellasia | BusinessWire | 5:00 PM − LIVTENCITY Is the First and Only Treatment Approved for This Indication by…